| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA630397 | A | Mouse plasma levels are obtained 24 hr after oral administration of 100 mg/kg of compound. | Mus musculus | 8 | organism-based format | Scientific Literature | ||
| 2. | ALA630398 | A | Mouse plasma levels are obtained 6 hr after oral administration of 100 mg/kg of compound. | Mus musculus | 9 | organism-based format | Scientific Literature | ||
| 3. | ALA678320 | B | FGFR-1 (FTK) inhibitory activity at 2 uM of ATP in vitro. | 33 | single protein format | Scientific Literature | |||
| 4. | ALA800094 | F | Percent inhibition of VEGF-mediated estradiol benzoate-induced rat uterus weight gain at 60 mg/kg oral dose | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
| 5. | ALA811931 | B | In vitro vascular endothelial growth factor receptor 1 inhibitory activity at 2 uM of ATP. | 35 | single protein format | Scientific Literature | |||
| 6. | ALA812620 | B | Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro. | 33 | single protein format | Scientific Literature | |||
| 7. | ALA852072 | B | Ratio of IC50 of FGFR-1 (FTK) to VEGFR-1 (Flt). | 28 | assay format | Scientific Literature | |||
| 8. | ALA852073 | B | Ratio of IC50 of FGFR-1 (FTK) to VEGFR-2 (KDR). | 29 | protein format | Scientific Literature | |||
| 9. | ALA3301364 | P | ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM | 1,763 | small-molecule physicochemical format | AstraZeneca Deposited Data | |||
| 10. | ALA3778237 | B | Inhibition of human RET cytoplasmic domain (658 to 1114 residues) expressed in baculovirus system preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay | Homo sapiens | 44 | assay format | Scientific Literature | ||
| 11. | ALA3778238 | B | Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay | Homo sapiens | 44 | cell-based format | Scientific Literature | ||
| 12. | ALA3778239 | B | Selectivity ratio of IC50 for recombinant His-tagged human KDR expressed in insect Sf21 cells to IC50 for human RET cytoplasmic domain (658 to 1114 residues) expressed in baculovirus system | Homo sapiens | 44 | cell-based format | Scientific Literature | ||
| 13. | ALA3778240 | B | Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay | Homo sapiens | 35 | cell-based format | Scientific Literature | ||
| 14. | ALA3778241 | B | Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay | Homo sapiens | 35 | cell-based format | Scientific Literature | ||
| 15. | ALA3776063 | B | Selectivity ratio of IC50 for KDR inhibition (unknown origin) expressed in mouse BA/F3 cells to IC50 for KIF5B/RET inhibition (unknown origin) expressed in mouse BA/F3 cells | Homo sapiens | 35 | cell-based format | Scientific Literature | ||
| 16. | ALA3776064 | A | Intrinsic clearance in iv dosed CD1 mouse assessed per 10'6 cells by LC-MS/MS analysis | Mus musculus | 11 | organism-based format | Scientific Literature | ||
| 17. | ALA3776065 | A | Cytotoxicity in mouse BA/F3 cells after 48 hrs by Cell titre glo-based luminescence assay | Mus musculus | 11 | cell-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!